Quick Facts

• Hypertension: Supports the management of high blood pressure.
• Angina Pectoris: May assist in the long-term management of chest discomfort related to heart disease.
• Myocardial Infarction: Is indicated for reducing cardiovascular events after a heart attack.
• Heart Failure: Used to support patients managing chronic heart failure to reduce the need for hospitalization.

What Lopresor SR Treats: Main Uses and Benefits

Lopresor SR (metoprolol succinate extended-release) is a prescription medication utilized in cardiovascular care. Its main therapeutic domain is to help achieve and sustain lower blood pressure in individuals diagnosed with hypertension. Maintaining healthy blood pressure is a key part of comprehensive cardiovascular risk management. The medication is also indicated for the long-term support of patients with angina pectoris, a condition involving chest pain. This use is intended to reduce the occurrence of angina episodes.

Furthermore, Lopresor SR is used to improve outcomes for patients following a myocardial infarction (heart attack). This treatment may reduce the risk of additional cardiovascular events and support long-term patient stability. For individuals with chronic heart failure, this drug is approved for use alongside other established therapies to support heart function and may reduce the requirement for hospital admission related to the condition. Consulting with a healthcare provider is essential to determine if this prescription medication is suitable for individual health needs. The precise benefits may vary among patients.

Lopresor SR (metoprolol succinate extended-release) is an eligibility-restricted medicine, with strict contraindications that prohibit its use in certain patient populations. The official regulatory documents define clear boundaries for who can and cannot use this medicine.

Contraindicated Populations

Use is formally prohibited for patients with:

• Severe bradycardia (very slow heart rate).
• Second or third-degree heart block (a serious heart rhythm disorder).
• Cardiogenic shock or decompensated heart failure (uncontrolled, severe heart failure).
• Sick sinus syndrome (unless a permanent pacemaker is in place).
• Known hypersensitivity or allergy to metoprolol or any component of the product, or to other beta-blockers.

Eligibility-Related Restrictions and Considerations

Use also requires caution and monitoring in patients with diabetes (as it may mask signs of low blood sugar) and those with pheochromocytoma (must be given with an alpha-blocker).

Interactions with other medicines and products

This section outlines documented interactions for Lopresor SR (metoprolol succinate extended-release) based strictly on authoritative regulatory labeling.

Pharmacokinetic Interactions

Lopresor SR is primarily metabolized by the CYP2D6 enzyme. Co-administration with drugs that inhibit this enzyme can significantly increase metoprolol plasma concentrations. Strong inhibitors include, but are not limited to, quinidine, fluoxetine, paroxetine, and propafenone. This increase in systemic exposure may diminish the drug's cardioselectivity. Individuals identified as CYP2D6 poor metabolizers also exhibit these several-fold increases in metoprolol blood levels.

Pharmacodynamic Interactions

Procedural and Non-Medicinal Interactions

• Clonidine: Lopresor SR should be withdrawn gradually several days before the final withdrawal of clonidine to prevent rebound hypertension.
• Food: Taking the tablet with or immediately following a meal increases the absorption of metresoprolol.
• Alcohol: Consumption may lead to additive hypotensive effects.

Lopresor SR's mechanism centers on acting as a competitive antagonist at the beta1 -adrenergic receptors (beta1 ARs), the primary targets in cardiac tissue. This action directly blocks the stimulatory effects of catecholamines (like adrenaline), preventing the agonist-driven activation of the Gs-protein coupled pathway, which reduces calcium influx in cardiac cells. The molecular event results in a reduction of the heart rate (negative chronotropy) and the force of contraction (negative inotropy), which decreases the kinetic energy demands and oxygen consumption of the myocardium. Beyond its cardiac effects, the drug's mechanism also influences systemic regulation by engaging beta1 receptors located on the juxtaglomerular cells of the kidney. The antagonism at this site suppresses the release of Renin, the enzyme that initiates the Renin-Angiotensin-Aldosterone System (RAAS). This modulation limits the formation of vasoconstrictors, which alters systemic vascular dynamics. This cardioselective mechanism is concentration-dependent and subject to constraints; specifically, at higher plasma levels, the drug's selectivity for beta1 receptors diminishes, causing antagonism of beta2 -adrenergic receptors in other tissues.

Lopresor SR (metoprolol succinate extended-release) is administered once daily for the long-term management of cardiovascular conditions. The drug is taken orally and dosing is highly individualized through a process of careful adjustment.

General Administration Instructions

The extended-release nature of the tablet requires specific handling to ensure proper, sustained delivery of the medicine over 24 hours.

Dosing Schedules and Adjustments

Initial and maintenance dosing ranges are specific to the condition being treated, and dose increases are managed on a defined schedule.

For pediatric patients (6 years and older) with hypertension, the starting dose is based on body weight, with a maximum initial dose of 50 mg once daily. In cases of severe hepatic impairment, a lower starting dose and cautious, gradual titration are required. If treatment is to be discontinued, the dosage must be gradually reduced over a period of 1 to 2 weeks.

Research Evidence / Overview of Studies for Lopresor SR

Evidence for Use in Managing High Blood Pressure (Hypertension)

Research has examined the use of this medication in people with high blood pressure, a condition monitoring physiological strain or stress. Randomized Controlled Trials (RCTs) were used in research exploring how outcomes related to systemic or functional imbalance change measured during the study period. These trials tracked changes in blood pressure and explored whether use of this drug was associated with changes in the incidence of major cardiovascular events. What remains uncertain is that many findings are related to the class of drug, and comparative evidence is lacking against every newer generation of medication.

Evidence for Use in Chronic Heart Failure

The evidence for this indication comes largely from landmark, large-scale, placebo-controlled RCTs, which focused on conditions marked by functional limitations. These studies monitored core clinical outcomes, including metrics related to survival rates and the number of hospitalizations related to heart failure. Findings describe patterns observed in the studies where patients receiving the study drug was observed in studies monitoring metrics related to survival rates and hospitalization compared to those on placebo. The results apply primarily to the populations studied, who were stable and already receiving other standard therapies.

Evidence for Use in Angina Pectoris and Post-Heart Attack Care

This section details studies relevant in trials assessing short-term or episodic symptom patterns associated with physical discomfort and foundational trials following a major heart event. Research was studied for its application in conditions characterized by fluctuating manifestations of chest discomfort. Trials monitored outcomes such as the measured frequency of these episodes and metrics related to daily functioning. Foundation trials for post-heart attack care examined the subsequent incidence of cardiovascular events and mortality. Some of these foundational data were derived from older trials.

Long-Term Studies and Follow-Up Duration

Studies were evaluated in research settings where patients was observed in defined time intervals, sometimes extending for several years. For some indications, key follow-up durations were limited to intermediate periods, and data for long-term outcomes remains insufficient.

What Is Still Uncertain About Lopresor SR Research

Research was evaluated in specific groups, including children aged 6 to 16 years for hypertension and the elderly for heart failure. Findings were mixed, or data are still emerging for certain highly specific populations. Comparative evidence is lacking against all newer agents in the same drug class. Additionally, the results apply only to the populations studied and do not provide individual predictions. Limited information for long-term outcomes exists in every single scenario.

Common questions about Lopresor SR (FAQ)

Q: What is the main difference between Lopresor SR and regular Lopresor?

Lopresor SR is an extended-release (ER) formulation, meaning it is specifically designed to release the metoprolol gradually into the bloodstream over a full 24-hour period. This controlled delivery aims to maintain stable medicine levels and avoid the high peak concentrations sometimes seen with immediate-release (IR) forms of the drug.

Q: How quickly should I expect Lopresor SR to start working?

Lopresor SR is a long-term treatment, and the expected therapeutic effect is gradual rather than immediate. According to official product information, when a dosage change is made, the maximum effect of that adjustment is typically reached after one week of continuous use.

Q: Will I feel different immediately after starting Lopresor SR?

The extended-release formulation is specifically engineered for smooth, sustained delivery, intending to avoid dramatic fluctuations in the bloodstream. While some individuals may notice common effects like tiredness or dizziness, the intended therapeutic benefit develops gradually over time.

Q: Is Lopresor SR known to cause weight gain?

Weight gain is not commonly listed as an adverse reaction in the main clinical trial data for metoprolol. However, this effect has been reported in post-marketing experience and is a known potential effect associated with some beta-blocker medications.

Q: Is it normal to have vivid dreams when taking Lopresor SR?

Nightmares and other types of sleep disturbances, including vivid dreams, are reported in the official product information. Nightmares are listed as an uncommon adverse reaction, meaning they affect a small percentage of people.

Q: Does Lopresor SR affect men's sexual function?

Regulatory documents describe that impotence and other forms of sexual dysfunction are reported adverse reactions. These effects are classified as rare in the product information.

Q: Are there any common over-the-counter medicines or supplements that interact with Lopresor SR?

The regulatory label includes warnings of potential interactions with common products. For instance, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen, may reduce the blood pressure-lowering effect of Lopresor SR. Some herbal supplements can also affect how metoprolol is processed by the body.

Q: Can drinking coffee or caffeine impact how Lopresor SR works?

Official information notes that substances that increase heart activity or blood pressure may potentially counteract the effects of metoprolol. Since caffeine is known to stimulate the heart and raise blood pressure, a high intake may potentially influence the intended blood pressure and heart rate effects of the drug.

Q: Is Lopresor SR safe for older adults (seniors)?

Clinical studies have included geriatric patients, and no overall differences in safety were found compared to younger adults. However, for certain conditions, special consideration is often given, which may involve careful and gradual dosage adjustment for this population.

Q: Can Lopresor SR make coldness in my hands and feet worse?

The official adverse reactions section notes a possibility of a cold feeling in the hands and feet. For individuals who already have peripheral vascular disease, the drug may rarely exacerbate symptoms, including coldness or other circulatory issues.

Q: Is it important to monitor my heart rate while taking Lopresor SR?

The drug works to slow heart activity, and since very slow heart rate (bradycardia) is both a common adverse reaction and a condition that prevents use, tracking the heart rate is a necessary consideration.

Q: Is there a generic version of Lopresor SR available?

Official regulatory data indicates that the generic equivalent, metoprolol succinate extended-release tablets, is approved and available.

Q: Is Lopresor SR generally considered safe for long-term management of high blood pressure?

According to the official regulatory documents, Lopresor SR is indicated for the long-term management of chronic conditions, including high blood pressure. The designation for long-term treatment reflects a benefit-risk profile developed from clinical data available to regulators.

Q: Can Lopresor SR cause constipation or stomach upset?

Gastrointestinal symptoms are listed among the potential adverse reactions in the official product information. Official product information reports symptoms such as constipation, nausea, vomiting, gastric pain, and diarrhea.

Q: Do I need to check my blood pressure every day when taking this medicine?

Since the medicine is prescribed to manage blood pressure, and dosage adjustments are guided by blood pressure response, regular monitoring is a necessary consideration. However, the specific frequency of monitoring (e.g., daily) is a clinical decision and is not dictated by the official drug label itself.

Q: Can Lopresor SR be taken with common pain relievers like ibuprofen?

Official regulatory documents warn that taking Lopresor SR with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which includes common pain relievers like ibuprofen, may reduce the blood pressure-lowering effect of metoprolol.

Q: Is the brand name Lopresor SR still available, or has it been replaced by metoprolol succinate extended-release?

The brand name Lopresor SR continues to be listed and fully referenced in official drug documentation alongside its generic name. This status indicates that the brand-name product remains available as approved by regulatory agencies.

Q: What is the half-life of Lopresor SR?

The half-life refers to the time it takes for half of the medicine to be cleared from the bloodstream. For metoprolol, this time averages between 3 to 7 hours, but the extended-release formulation ensures the drug is delivered over a full 24-hour period.

Q: Does Lopresor SR interact with herbal supplements like St. John's Wort?

Official regulatory information indicates that St. John’s Wort can interact with Lopresor SR. The supplement may affect the rate at which metoprolol is removed from the body, leading to potential changes in the concentration of the drug in the bloodstream.

Q: Can Lopresor SR cause difficulty sleeping?

Difficulty sleeping, known as insomnia, is listed in the official product information as an adverse reaction. Insomnia is classified as an uncommon effect, meaning it is reported in a small number of patients.

Q: Can Lopresor SR cause hair loss?

Hair loss, also known as alopecia, is described in the official regulatory documents as a rare adverse reaction. This means it has been reported in fewer than 1 in 1,000 people.

Q: Is it possible to overdose on Lopresor SR?

The official prescribing information includes a dedicated section describing the risks and symptoms associated with overdosage. Symptoms may include an extremely slow heart rate, very low blood pressure, and a bluish discoloration of the skin or nails.

Q: Does the medicine contain lactose or other common allergens?

The complete list of inactive ingredients, or excipients, is included in the full official prescribing information. This section details all components, including common substances like lactose, to identify potential allergens.

How to Store and Dispose of Lopresor SR?

Storage Conditions:

Lopresor SR (metoprolol succinate extended-release tablets) should be stored at room temperature, away from excess heat and moisture, and should never be stored in a bathroom. Keep the medication in the container it came in, with the safety cap tightly closed.

Safety and Handling:

It is essential to keep this medication out of reach and sight of children. Store the product in a safe, high-up location and always ensure safety caps are locked. The tablets should not be crushed or chewed.

Disposal Instructions:

To dispose of Lopresor SR, first check for local drug take-back programs. If none are available, the medication is generally disposed of in the household trash. The recommended method involves removing the drug from its original container, mixing the whole tablets with an undesirable substance (such as coffee grounds or cat litter), and placing the mixture in a sealed bag or container before discarding it in the trash. Always scratch out all personal information on the prescription label before recycling or discarding the empty packaging.